

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

February 5, 2026

**Consolidated Financial Summary  
for the First Nine Months of the Fiscal Year Ending March 31, 2026  
(Under Japanese GAAP)**

**Listed Company:** Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/english/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Koichi Tamura, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date to commence dividend payments: –

Preparation of supplementary documents to the financial results: None

Holding of financial results presentation: None

(Amounts under a million yen are truncated.)

**1. Consolidated Financial Highlights (April 1, 2025 through December 31, 2025)**

**(1) Consolidated Financial Results (cumulative)**

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
December 31, 2025	64,077	(1.1)	8,566	(16.4)	7,286	(31.7)	5,554	(32.5)
December 31, 2024	64,773	11.8	10,246	8.0	10,661	12.9	8,226	(2.3)

Note: Comprehensive income: For the nine months ended December 31, 2025: 8,498 million yen [14.9%]

For the nine months ended December 31, 2024: 7,394 million yen [(50.7)%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2025	126.00	–
December 31, 2024	186.63	–

**(2) Consolidated Financial Position**

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
December 31, 2025	166,225	96,176	57.8
March 31, 2025	159,171	89,797	56.3

Reference: Equity: As of December 31, 2025: 96,014 million yen

As of March 31, 2025: 89,539 million yen

**2. Dividends**

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2025	–	23.00	–	24.00	47.00
Year ending March 31, 2026	–	24.00	–		
Year ending March 31, 2026 (Forecast)				24.00	48.00

Note: Revision of the forecast of dividends most recently announced: None

### 3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026 (April 1, 2025 through March 31, 2026)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	90,000	3.1	12,000	(1.6)	12,000	(6.5)	9,500	(4.4)	215.52

Note: Revision of the financial forecast most recently announced: None

#### \* Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Inclusion: – (Company name: –) Exclusion: 1 Company (Kenso-Seiyaku Co., Ltd.)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

- 1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- 2) Changes in accounting policies due to other reasons: None
- 3) Changes in accounting estimates: None
- 4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of December 31, 2025: 51,119,190 shares As of March 31, 2025: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of December 31, 2025: 7,039,792 shares As of March 31, 2025: 9,039,667 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the nine months ended December 31, 2025: 44,079,480 shares

For the nine months ended December 31, 2024: 44,079,624 shares

Notes: 1. Based on the resolution at a meeting of the Board of Directors held on August 5, 2025, the Company cancelled 1,000,000 treasury shares as of August 27, 2025.

2. Based on the resolution at a meeting of the Board of Directors held on November 5, 2025, the Company cancelled 1,000,000 treasury shares as of November 26, 2025.

\* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit corporation: None

\* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.